Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MREO |
---|---|---|
09:32 ET | 75434 | 4.705 |
09:34 ET | 34634 | 4.8 |
09:36 ET | 42636 | 4.8 |
09:38 ET | 18011 | 4.795 |
09:39 ET | 15620 | 4.772 |
09:41 ET | 42855 | 4.825 |
09:43 ET | 3750 | 4.7883 |
09:45 ET | 12581 | 4.7705 |
09:48 ET | 20036 | 4.785 |
09:50 ET | 30890 | 4.885 |
09:52 ET | 19171 | 4.875 |
09:54 ET | 21384 | 4.89 |
09:56 ET | 44188 | 4.8876 |
09:57 ET | 40263 | 4.8951 |
09:59 ET | 12765 | 4.885 |
10:01 ET | 11169 | 4.94 |
10:03 ET | 44638 | 4.9332 |
10:06 ET | 22688 | 4.98 |
10:08 ET | 44304 | 4.92 |
10:10 ET | 27836 | 4.94 |
10:12 ET | 14515 | 4.96 |
10:14 ET | 5881 | 4.995 |
10:15 ET | 41395 | 5.0099 |
10:17 ET | 5100 | 5.0158 |
10:19 ET | 23578 | 4.95 |
10:21 ET | 20836 | 4.925 |
10:24 ET | 19064 | 4.92 |
10:26 ET | 20676 | 4.91 |
10:28 ET | 13619 | 4.9101 |
10:30 ET | 25827 | 4.9101 |
10:32 ET | 4597 | 4.915 |
10:33 ET | 3704 | 4.92 |
10:35 ET | 5536 | 4.92 |
10:37 ET | 11286 | 4.915 |
10:39 ET | 9806 | 4.92 |
10:42 ET | 11271 | 4.92 |
10:44 ET | 17023 | 4.92 |
10:46 ET | 3400 | 4.91 |
10:48 ET | 5160 | 4.915 |
10:50 ET | 20420 | 4.8525 |
10:51 ET | 27137 | 4.8513 |
10:53 ET | 14654 | 4.83 |
10:55 ET | 5300 | 4.83 |
10:57 ET | 8197 | 4.8506 |
11:00 ET | 7355 | 4.8899 |
11:02 ET | 9356 | 4.9 |
11:04 ET | 7033 | 4.914 |
11:06 ET | 7250 | 4.925 |
11:08 ET | 6063 | 4.945 |
11:09 ET | 1335 | 4.95 |
11:11 ET | 2004 | 4.93 |
11:13 ET | 8503 | 4.88 |
11:15 ET | 2879 | 4.88 |
11:18 ET | 4028 | 4.88 |
11:20 ET | 6082 | 4.86 |
11:22 ET | 4695 | 4.85 |
11:24 ET | 8988 | 4.855 |
11:26 ET | 6259 | 4.855 |
11:27 ET | 28586 | 4.86 |
11:29 ET | 660 | 4.87 |
11:31 ET | 102 | 4.875 |
11:33 ET | 1637 | 4.8701 |
11:36 ET | 3264 | 4.88 |
11:38 ET | 1146 | 4.8882 |
11:40 ET | 12137 | 4.93 |
11:42 ET | 7252 | 4.97 |
11:44 ET | 100 | 4.97 |
11:45 ET | 16470 | 4.9403 |
11:47 ET | 6050 | 4.92 |
11:49 ET | 20261 | 4.95 |
11:51 ET | 4124 | 4.9398 |
11:54 ET | 3462 | 4.93 |
11:56 ET | 3207 | 4.915 |
11:58 ET | 7379 | 4.92 |
12:00 ET | 10679 | 4.895 |
12:02 ET | 14597 | 4.86 |
12:03 ET | 6825 | 4.86 |
12:05 ET | 10977 | 4.85 |
12:07 ET | 1854 | 4.85 |
12:09 ET | 7205 | 4.85 |
12:12 ET | 30934 | 4.79 |
12:14 ET | 7304 | 4.79 |
12:16 ET | 8239 | 4.79 |
12:18 ET | 10461 | 4.8 |
12:20 ET | 5677 | 4.7945 |
12:21 ET | 14720 | 4.7901 |
12:23 ET | 2744 | 4.795 |
12:25 ET | 8695 | 4.79 |
12:27 ET | 1400 | 4.795 |
12:30 ET | 6745 | 4.82 |
12:32 ET | 1475 | 4.835 |
12:34 ET | 2200 | 4.8394 |
12:36 ET | 600 | 4.845 |
12:38 ET | 1420 | 4.85 |
12:39 ET | 100 | 4.855 |
12:43 ET | 15918 | 4.81 |
12:45 ET | 2850 | 4.82 |
12:48 ET | 2240 | 4.83 |
12:50 ET | 8343 | 4.81 |
12:52 ET | 1800 | 4.81 |
12:54 ET | 599 | 4.82 |
12:56 ET | 500 | 4.82 |
12:57 ET | 9199 | 4.79 |
12:59 ET | 1100 | 4.795 |
01:01 ET | 5250 | 4.79 |
01:03 ET | 1520 | 4.79 |
01:06 ET | 708 | 4.79 |
01:08 ET | 2811 | 4.77 |
01:10 ET | 6762 | 4.76 |
01:12 ET | 2429 | 4.75 |
01:14 ET | 16199 | 4.72 |
01:15 ET | 1629 | 4.725 |
01:17 ET | 9300 | 4.72 |
01:19 ET | 1299 | 4.725 |
01:24 ET | 1455 | 4.725 |
01:26 ET | 15292 | 4.72 |
01:28 ET | 5872 | 4.72 |
01:30 ET | 4653 | 4.7278 |
01:32 ET | 450 | 4.7287 |
01:33 ET | 5955 | 4.725 |
01:35 ET | 3290 | 4.7101 |
01:37 ET | 2502 | 4.71 |
01:39 ET | 3200 | 4.71 |
01:42 ET | 3000 | 4.71 |
01:44 ET | 17149 | 4.725 |
01:46 ET | 14448 | 4.77 |
01:48 ET | 8401 | 4.75 |
01:50 ET | 1484 | 4.75 |
01:51 ET | 5656 | 4.75 |
01:53 ET | 4394 | 4.79 |
01:55 ET | 3650 | 4.82 |
01:57 ET | 2918 | 4.825 |
02:00 ET | 350 | 4.825 |
02:02 ET | 3468 | 4.81 |
02:04 ET | 1435 | 4.81 |
02:06 ET | 450 | 4.815 |
02:08 ET | 856 | 4.81 |
02:09 ET | 1069 | 4.8099 |
02:11 ET | 118 | 4.805 |
02:13 ET | 1508 | 4.795 |
02:15 ET | 1028 | 4.8098 |
02:18 ET | 3400 | 4.7999 |
02:20 ET | 750 | 4.7948 |
02:22 ET | 918 | 4.79 |
02:24 ET | 4956 | 4.775 |
02:26 ET | 6298 | 4.79 |
02:27 ET | 1200 | 4.795 |
02:29 ET | 3572 | 4.775 |
02:31 ET | 2287 | 4.79 |
02:33 ET | 222 | 4.7999 |
02:36 ET | 3435 | 4.77 |
02:38 ET | 1908 | 4.78 |
02:40 ET | 5334 | 4.7901 |
02:42 ET | 5399 | 4.79 |
02:44 ET | 7027 | 4.805 |
02:45 ET | 200 | 4.8068 |
02:47 ET | 1110 | 4.805 |
02:49 ET | 1200 | 4.81 |
02:51 ET | 2017 | 4.82 |
02:54 ET | 5849 | 4.82 |
02:56 ET | 912 | 4.814 |
02:58 ET | 875 | 4.81 |
03:00 ET | 4150 | 4.8099 |
03:02 ET | 338 | 4.8078 |
03:03 ET | 1200 | 4.805 |
03:05 ET | 100 | 4.805 |
03:07 ET | 5096 | 4.78 |
03:09 ET | 191 | 4.78 |
03:12 ET | 900 | 4.785 |
03:14 ET | 5327 | 4.805 |
03:16 ET | 3971 | 4.805 |
03:18 ET | 2600 | 4.8097 |
03:20 ET | 1602 | 4.815 |
03:21 ET | 3245 | 4.825 |
03:23 ET | 5530 | 4.8399 |
03:25 ET | 8500 | 4.85 |
03:27 ET | 6090 | 4.84 |
03:30 ET | 2736 | 4.835 |
03:32 ET | 6246 | 4.84 |
03:34 ET | 4240 | 4.815 |
03:36 ET | 4672 | 4.815 |
03:38 ET | 11703 | 4.805 |
03:39 ET | 21210 | 4.825 |
03:41 ET | 27025 | 4.8299 |
03:43 ET | 8261 | 4.8 |
03:45 ET | 1387 | 4.79 |
03:48 ET | 13653 | 4.81 |
03:50 ET | 3253 | 4.8 |
03:52 ET | 3090 | 4.805 |
03:54 ET | 1543 | 4.8 |
03:56 ET | 3630 | 4.805 |
03:57 ET | 9079 | 4.815 |
03:59 ET | 57404 | 4.83 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Mereo BioPharma Group PLC | 743.1M | -14.7x | --- |
Tarsus Pharmaceuticals Inc | 971.2M | -5.8x | --- |
Immunome Inc | 927.8M | -2.7x | --- |
Relay Therapeutics Inc | 964.0M | -2.9x | --- |
Viridian Therapeutics Inc | 961.5M | -3.5x | --- |
89Bio Inc | 937.8M | -4.5x | --- |
Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $743.1M |
---|---|
Revenue (TTM) | $10.5M |
Shares Outstanding | 153.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.97 |
EPS | $-0.33 |
Book Value | $0.46 |
P/E Ratio | -14.7x |
Price/Sales (TTM) | 71.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -416.58% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.